Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

CG Oncology (CGON) Change in Receivables (2024 - 2025)

CG Oncology filings provide 2 years of Change in Receivables readings, the most recent being $301000.0 for Q4 2025.

On a quarterly basis, Change in Receivables fell 53.26% to $301000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $320000.0, a N/A change, with the full-year FY2025 number at $320000.0, down 53.56% from a year prior.
Change in Receivables hit $301000.0 in Q4 2025 for CG Oncology, up from $238000.0 in the prior quarter.
In the past five years, Change in Receivables ranged from a high of $644000.0 in Q4 2024 to a low of -$436000.0 in Q1 2025.